Drug discovery is harder than it used to be, says Technology Review's Susan Young. Pharma pipelines are freezing up and fewer drugs are getting past early-stage testing. Further, there are entrepreneurs who have new ideas, but no money to bring them to completion, Young says. So pharma, biotech, and academia are trying to solve their collective problems by coming together with venture capitalists to create new drug discovery funding models, she adds.